Trial Profile
A multicenter Phase 2 clinical trial evaluating efficacy of tomivosertib (eFT508) and KEYTRUDA (pembrolizumab) combination for the treatment of patients with metastatic triple negative breast cancer (TNBC)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2018
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Tomivosertib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 24 Oct 2018 New trial record
- 16 Oct 2018 According to an eFFECTOR Therapeutics media release, enrollment is expected to begin in early 2019.